Advitech signs deal with Jamieson Labs to introduce Dermylex for psoriasis

By E. Janene Geiss

Philadelphia, March 10 - Advitech Inc. announced Friday that it has reached an agreement with Jamieson Laboratories Ltd. to conduct a special product introduction program for Dermylex, its product for the management of mild to moderate psoriasis.

Under this program, Jamieson said it will make available Advitech's newly developed and clinically proven natural product for psoriasis in the Toronto metropolitan area and in Quebec City, according to a company news release.

Jamieson said it expects that Dermylex will be available in late March in designated pharmacies and health food stores.

Advitech and Jamieson said they have also agreed in principle regarding the marketing and distribution of its psoriasis product Dermylex for all Canadian provinces.

"The Jamieson and Quest brands and organization have an outstanding reputation in Canada and their experience in launching successful products for health-conscious consumers is going to be very important for us," Renaud Beauchesne, chief executive officer of Advitech, said in the release.

Dermylex is Advitech's orally administered product for mild to moderate plaque psoriasis. Dermylex is based on Advitech's XP-828L, a bioactive ingredient with proven clinical efficacy.

The company reported in 2005 positive results from its phase 2 clinical trial of XP-828L for treating mild to moderate psoriasis. The 112-day, multi-center, double blind, placebo-controlled study involving 84 patients confirmed the efficacy and excellent safety profile of XP-828L for treating mild to moderate psoriasis.

Jamieson, based in Toronto, Ont., is Canada's largest manufacturer and distributor of advanced natural health care products. The company exports to more than 45 countries including the United States, China, Japan, Hong Kong, Korea and Singapore.

Advitech is a Montreal biotechnology company specializing in the development of bioactive ingredients from dairy proteins. Its key focus areas are in the fields of immunology and inflammation. Its main platform, XP-828L, is a growth factor complex aimed at treating psoriasis, inflammatory bowel diseases and other chronic immune-mediated inflammatory diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.